{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:51:23Z","timestamp":1790913083185,"version":"4.1.0"},"reference-count":205,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008595","name":"Medical Department of the Margarete and Walter Lichtenstein Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006069","name":"Cancel League of Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017295","name":"Holcim Foundation for the Promotion of Scientific Further Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017295","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105312","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:01:44Z","timestamp":1775026904000},"page":"105312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Immunotherapy advancements in high-grade serous ovarian cancer: From promise to practice"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2816-1351","authenticated-orcid":false,"given":"Martin","family":"Heidinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Stiegeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatios","family":"Petousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kacperczyk-Bartnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Oseledchyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kurzeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Heinzelmann-Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1574-6572","authenticated-orcid":false,"given":"Tibor A.","family":"Zwimpfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.critrevonc.2026.105312_bib1","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib2","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1016\/j.annonc.2024.08.812","volume":"35","author":"Aghajanian","year":"2024","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105312_bib3","doi-asserted-by":"crossref","DOI":"10.1593\/neo.12442","article-title":"Differential Roles of uPAR in Peritoneal Ovarian Carcinomatosis","volume":"14","author":"Al-Hassan","year":"2012","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41467-025-56527-0","article-title":"Unlocking the potential of engineered immune cell therapy for solid tumors","volume":"16","author":"Albarr\u00e1n-Fern\u00e1ndez","year":"2025","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105312_bib5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10585-005-2893-8","article-title":"ICAM-1 mediated peritoneal carcinomatosis, A target for therapeutic intervention","volume":"22","author":"Alkhamesi","year":"2005","journal-title":"Clin. & Exp. Metastas-.-."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial","volume":"36","author":"Alvarez Secord","year":"2025","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib7","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1038\/s41467-025-58440-y","article-title":"Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial","volume":"16","author":"Aronson","year":"2025","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105312_bib8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/PGP.0b013e3182800ad5","article-title":"The stem-cell profile of ovarian surface epithelium is reproduced in the oviductal fimbriae, with increased stem-cell marker density in distal parts of the fimbriae","volume":"32","author":"Auersperg","year":"2013","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105312_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","article-title":"Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer","volume":"27","author":"Berek","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib11","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41467-025-56482-w","article-title":"The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial","volume":"16","author":"Block","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105312_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2024.12.011","article-title":"Incorporating immune checkpoint inhibitors in epithelial ovarian cancer","volume":"193","author":"Bogani","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.886170","article-title":"Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: a focus on the immune system","volume":"13","author":"Bound","year":"2022","journal-title":"Front. Genet."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105312_bib14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105312_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bjc.2016.172","article-title":"CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer","volume":"115","author":"Bronger","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ygyno.2003.12.034","article-title":"Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers","volume":"93","author":"Burleson","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105312_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10585-004-5768-5","article-title":"Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers","volume":"21","author":"Burleson","year":"2005","journal-title":"Clin. & Exp. Metastas-.-."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib18","doi-asserted-by":"crossref","first-page":"10828","DOI":"10.1038\/ncomms10828","article-title":"Protection from septic peritonitis by rapid neutrophil recruitment through omental high endothelial venules","volume":"7","author":"Buscher","year":"2016","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105312_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1006\/gyno.1995.1214","article-title":"Expression and Function of \u03b21 and \u03b1v\u03b23 Integrins in Ovarian Cancer","volume":"58","author":"Cannistra","year":"1995","journal-title":"Gynecol. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105312_bib20","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/onc.2011.429","article-title":"Tissue transglutaminase links TGF-\u03b2, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer","volume":"31","author":"Cao","year":"2012","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105312_bib21","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/ijc.10433","article-title":"Involvement of \u03b1v\u03b2 3 integrin and disruption of endothelial fibronectin network during the adhesion of the human ovarian adenocarcinoma cell line IGROV1 on the human umbilical vein cell extracellular matrix","volume":"99","author":"Carreiras","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105312_bib22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105312_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105312_bib25","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-13-1185","article-title":"A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside","volume":"19","author":"Chiang","year":"2013","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10555-014-9538-9","article-title":"Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches","volume":"34","author":"Choi","year":"2015","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105312_bib27","article-title":"Development of Therapeutic Vaccines for Ovarian Cancer","volume":"8","author":"Chow","year":"2020","journal-title":"Vaccin. (Basel)"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib28","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ygyno.2021.07.003","article-title":"Dendritic cell-based immunotherapy (DCVAC\/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): a randomized, open-label, phase 2 trial","volume":"162","author":"Cibula","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib29","unstructured":"Clinicaltrials.gov (2026a). \"AZD5335 vs. Mirvetuximab Soravtansine in FR\u03b1-high and AZD5335 vs. Chemotherapy in FR\u03b1-low Platinum-resistant Ovarian Cancer (TREVI-OC-01).\" Retrieved 21.02.2026, 2026, from \u3008https:\/\/clinicaltrials.gov\/study\/NCT07218809\u3009."},{"key":"10.1016\/j.critrevonc.2026.105312_bib30","unstructured":"Clinicaltrials.gov (2026b). \"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01).\" Retrieved 21.02.2026, 2026, from \u3008https:\/\/clinicaltrials.gov\/study\/NCT07213804\u3009."},{"key":"10.1016\/j.critrevonc.2026.105312_bib31","doi-asserted-by":"crossref","first-page":"S1582","DOI":"10.1016\/j.annonc.2025.09.049","article-title":"LBA3 Pembrolizumab vs placebo plus weekly paclitaxel \u00b1; bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65\/KEYNOTE-B96 study","volume":"36","author":"Colombo","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib32","article-title":"B02-1 Pembrolizumab vs placebo plus weekly paclitaxel \u00b1 bevacizumab in platinum-resistant recurrent ovarian cancer: final analysis results from the randomized double-blind phase 3 ENGOT-ov65\/KEYNOTE-B96 study","volume":"2026","author":"Colombo","year":"2026","journal-title":"ESGO"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105312_bib33","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib34","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.immuni.2013.08.025","article-title":"Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2","volume":"39","author":"Cui","year":"2013","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105312_bib36","article-title":"CAR-T cell therapy in ovarian cancer: where are we now?","volume":"14","author":"Cutri-French","year":"2024","journal-title":"Diagn. (Basel)"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105312_bib37","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1158\/1078-0432.CCR-17-0647","article-title":"Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression","volume":"23","author":"Dalton","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105312_bib38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"issue":"34","key":"10.1016\/j.critrevonc.2026.105312_bib39","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.9908","article-title":"Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer","volume":"7","author":"Deng","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib40","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1038\/s41467-024-47271-y","article-title":"Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones","volume":"15","author":"Denisenko","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b Results From the JAVELIN Solid Tumor Trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","article-title":"Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Na\u00efve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study","volume":"30","author":"Drew","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105312_bib43","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.ccell.2021.10.008","article-title":"Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation","volume":"39","author":"Duraiswamy","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib44","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2411070","article-title":"High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1\u03b1 activity in neutrophils","volume":"13","author":"Emmanuelli","year":"2024","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib45","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib46","first-page":"1459","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.\" Nature","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2020","journal-title":"Communications"},{"key":"10.1016\/j.critrevonc.2026.105312_bib47","unstructured":"FDA, U. (2026). \"FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.\" Retrieved 19.02.2026, 2026, from \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or\u3009."},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105312_bib48","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death Ligand 1-Positive Cervical cancer: results from the phase Ib KEYNOTE-028 Trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105312_bib49","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1158\/1078-0432.CCR-21-4413","article-title":"An autologous dendritic cell vaccine promotes anticancer immunity in patients with ovarian cancer with low mutational burden and cold tumors","volume":"28","author":"Fucikova","year":"2022","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105312_bib50","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1479-5876-9-223","article-title":"Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials","volume":"9","author":"Fu\u010d\u00edkov\u00e1","year":"2011","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105312_bib51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0304-3835(95)03743-G","article-title":"Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis","volume":"91","author":"Gardner","year":"1995","journal-title":"Cancer Lett."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105312_bib52","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1158\/0008-5472.CAN-20-0521","article-title":"Multiomic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma","volume":"80","author":"Geistlinger","year":"2020","journal-title":"Cancer Res."},{"issue":"32","key":"10.1016\/j.critrevonc.2026.105312_bib53","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.25126","article-title":"Role of tumor microenvironment in ovarian cancer pathobiology","volume":"9","author":"Ghoneum","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105312_bib54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2024.04.001","article-title":"Adoptive T cell therapy for ovarian cancer","volume":"186","author":"Gitto","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105312_bib55","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann. Oncol."},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105312_bib56","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.24.00668","article-title":"Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41\/GEICO 69-O\/ANITA Phase III Trial","volume":"42","author":"Gonz\u00e1lez-Mart\u00edn","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib57","doi-asserted-by":"crossref","first-page":"S1586","DOI":"10.1016\/j.annonc.2025.09.055","article-title":"LBA43 NAPISTAR 1-01: A phase I dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC)","volume":"36","author":"Gonz\u00e1lez-Mart\u00edn","year":"2025","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-021-06480-5","article-title":"Immunotherapy toxicity: identification and management","volume":"192","author":"Gumusay","year":"2022","journal-title":"Breast Cancer Res Treat."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105312_bib59","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105312_bib60","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20080108","article-title":"Re-educating\u201d tumor-associated macrophages by targeting NF-\u03baB","volume":"205","author":"Hagemann","year":"2008","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105312_bib61","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-07-0118","article-title":"Ovarian cancer cell\u2013derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis","volume":"6","author":"Hagemann","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105312_bib62","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.4049\/jimmunol.176.8.5023","article-title":"Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype1","volume":"176","author":"Hagemann","year":"2006","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105312_bib63","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"33","key":"10.1016\/j.critrevonc.2026.105312_bib64","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib65","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105312_bib66","unstructured":"Hardy-Bessard, A.C., E. Pujade-Lauraine, R.G. Moore, F. Montestruc, A. Redondo, M.R. Mirza, D. Cibula, T.E. Ciuleanu, L. Gilbert, R. Eitan, F. Zagouri, S. Pignata, R. Glasspool, J. Pfisterer, R. Pha\u00ebton, C.K. Anderson, M. Rodrigues, L. Gaba, E. Bakirtzi, J.M. Fauci, E. Kalbacher, F.B. Musa, S. Gorman, L.R. Duska, L. Gladieff, P. Braly, F. Joly, J. Thomes Pepin, I. Ray-Coquard and K.N. Moore (n.d.). \"Dostarlimab and niraparib in primary advanced ovarian cancer.\" Annals of Oncology."},{"key":"10.1016\/j.critrevonc.2026.105312_bib67","article-title":"Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer","author":"Harter","year":"2025","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105312_bib68","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.critrevonc.2026.105312_bib69","doi-asserted-by":"crossref","DOI":"10.33425\/2639-8478.1055","article-title":"Vigil: personalized immunotherapy generating systemic Cytotoxic T Cell Response","volume":"3","author":"Herron","year":"2020","journal-title":"Cancer Sci. & Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105312_bib70","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","article-title":"CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105312_bib71","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/cncr.35126","article-title":"Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer","volume":"130","author":"Hinchcliff","year":"2024","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib72","article-title":"DNA repair gene mutations as predictors of immune checkpoint inhibitor response beyond tumor mutation burden","volume":"1","author":"Hsiehchen","year":"2020","journal-title":"Cell Rep. Med"},{"issue":"9951","key":"10.1016\/j.critrevonc.2026.105312_bib73","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105312_bib74","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41588-020-0630-5","article-title":"Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy","volume":"52","author":"Jim\u00e9nez-S\u00e1nchez","year":"2020","journal-title":"Nat. Genet"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105312_bib75","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1158\/1078-0432.CCR-20-1762","article-title":"The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval","volume":"26","author":"Jordan","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"6230","key":"10.1016\/j.critrevonc.2026.105312_bib76","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105312_bib77","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","article-title":"Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation","volume":"22","author":"Kandalaft","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105312_bib78","article-title":"Antibody-drug conjugates in gynecologic cancer","volume":"43","author":"Karpel","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105312_bib79","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1172\/JCI74778","article-title":"Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion","volume":"124","author":"Kenny","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"42","key":"10.1016\/j.critrevonc.2026.105312_bib80","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1038\/onc.2017.171","article-title":"Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis","volume":"36","author":"Klymenko","year":"2017","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib81","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ygyno.2021.09.025","article-title":"Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer","volume":"163","author":"Konecny","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib82","doi-asserted-by":"crossref","first-page":"S551","DOI":"10.1016\/j.annonc.2024.08.783","article-title":"721MO Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors","volume":"35","author":"Konecny","year":"2024","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105312_bib83","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"\"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105312_bib84","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1158\/0008-5472.CAN-06-2941","article-title":"The inflammatory cytokine tumor necrosis Factor-\u03b1 generates an autocrine tumor-promoting network in epithelial ovarian cancer cells","volume":"67","author":"Kulbe","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105312_bib85","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1016\/j.annonc.2024.08.774","article-title":"712MO Final overall survival (OS) from the phase III ATALANTE\/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)","volume":"35","author":"Kurtz","year":"2024","journal-title":"Ann. Oncol."},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105312_bib86","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1200\/JCO.23.00529","article-title":"\"Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized Phase III ATALANTE\/ENGOT-ov29 Trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105312_bib87","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002752","article-title":"Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer","volume":"9","author":"Kyi","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib88","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105312_bib89","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105312_bib90","article-title":"\"Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial","volume":"3","author":"Lan","year":"2022","journal-title":"Cell Rep. Med"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105312_bib91","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-22-2032","article-title":"Influence of genomic landscape on cancer immunotherapy for newly diagnosed ovarian cancer: biomarker analyses from the IMagyn050 Randomized Clinical Trial","volume":"29","author":"Landen","year":"2023","journal-title":"Clin. Cancer Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105312_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046858","article-title":"Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors","volume":"7","author":"Latifi","year":"2012","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib93","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1038\/s41467-024-47000-5","article-title":"Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma","volume":"15","author":"Le Saux","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105312_bib94","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2025.03.100","article-title":"ENCORE) Rinatabart sesutecan for patients with advanced ovarian cancer: results from dose expansion cohort B1 of phase I\/II study","volume":"200","author":"Lee","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105312_bib95","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e45","article-title":"\"Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial","volume":"33","author":"Lee","year":"2022","journal-title":"J. Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib96","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ijgo.15780","article-title":"Incorporation of immunotherapy and biological targeted therapy in primary anti-cancer treatment in gynecologic malignancy","volume":"167","author":"Lee","year":"2024","journal-title":"Int. J. Gynecol. & Obstet."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105312_bib97","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ijc.20778","article-title":"Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves \u03b1v integrins and the participation of MMP2","volume":"114","author":"Leroy-Dudal","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105312_bib98","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/cpt.2278","article-title":"Model-informed therapeutic dose optimization strategies for antibody-drug conjugates in oncology: what can we learn from US Food and Drug Administration-Approved Antibody-Drug Conjugates?","volume":"110","author":"Liao","year":"2021","journal-title":"Clin. Pharm. Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105312_bib99","doi-asserted-by":"crossref","DOI":"10.1200\/CCI.23.00207","article-title":"Prediction of effectiveness and toxicities of immune checkpoint inhibitors using real-world patient data","author":"Lippenszky","year":"2024","journal-title":"JCO Clin. Cancer Inform."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105312_bib100","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN Guidelines\u00ae Insights: ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer, Version 3.2024","volume":"22","author":"Liu","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib101","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12864-021-08265-y","article-title":"Combined PD-1\/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma","volume":"23","author":"Liu","year":"2022","journal-title":"BMC Genom."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105312_bib102","first-page":"5263","article-title":"Lysophosphatidic acid stimulates urokinase receptor (uPAR\/CD87) in Ovarian Epithelial Cancer Cells","volume":"35","author":"Lizalek","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2026.105312_bib103","doi-asserted-by":"crossref","DOI":"10.37536\/DIANAS.2019.8.1.39","article-title":"Prognostic and predictive immune gene signatures and correlation with homologous recombination deficiency in high grade serous ovarian cancer","volume":"8","author":"Lodewijk","year":"2019","journal-title":"Dianas"},{"key":"10.1016\/j.critrevonc.2026.105312_bib104","article-title":"Immunotherapy: reshape the tumor immune microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.10.069","article-title":"A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer","volume":"163","author":"Manyam","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105312_bib106","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.3390\/cancers12082223","article-title":"Antibody-drug conjugates: a promising novel therapy for the treatment of ovarian cancer","volume":"12","author":"Manzano","year":"2020","journal-title":"Cancers"},{"issue":"17_","key":"10.1016\/j.critrevonc.2026.105312_bib107","article-title":"Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29\/ENGOT-ov34 study","volume":"42","author":"Marm\u00e9","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib108","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00428-020-02751-6","article-title":"PD-1\/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma","volume":"477","author":"Martin de la Fuente","year":"2020","journal-title":"Virchows Arch."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105312_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines4020010","article-title":"Cancer Vaccines in Ovarian Cancer: How Can We Improve?","volume":"4","author":"Martin Lluesma","year":"2016","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10555-011-9337-5","article-title":"Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer","volume":"31","author":"Masoumi Moghaddam","year":"2012","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000375","article-title":"Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma","volume":"8","author":"Matsushita","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105312_bib112","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105312_bib113","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105312_bib114","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"\"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105312_bib115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib116","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105312_bib117","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.annonc.2020.05.019","article-title":"Prognostic gene expression signature for high-grade serous ovarian cancer","volume":"31","author":"Millstein","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib118","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2014elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105312_bib119","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70248","article-title":"Spatial genomics uncovers cytokines promoting ovarian tumour heterogeneity and immunotherapy resistance","volume":"15","author":"Mollaoglu","year":"2025","journal-title":"Clin. Transl. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105312_bib120","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/annonc\/mdx049","article-title":"\"A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study","volume":"28","author":"Monk","year":"2017","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105312_bib121","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib122","doi-asserted-by":"crossref","first-page":"S1223","DOI":"10.1016\/j.annonc.2024.08.2269","article-title":"LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC).","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105312_bib123","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105312_bib124","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105312_bib125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003645","article-title":"\"Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial","volume":"9","author":"Moreno","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"28","key":"10.1016\/j.critrevonc.2026.105312_bib126","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41388-025-03448-3","article-title":"Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment","volume":"44","author":"Narayana","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105312_bib127","unstructured":"National Cancer Institute Surveillance, E., and End Results Programme. (2026). \"Cancer Stat Facts: Ovarian Cancer.\" Retrieved 23.02.2026, from \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html\u3009."},{"key":"10.1016\/j.critrevonc.2026.105312_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105312_bib129","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0014-4827(85)90197-1","article-title":"\"Interactions of human ovarian tumor cells with human mesothelial cells grown on extracellular matrix: an in vitro model system for studying tumor cell adhesion and invasion","volume":"160","author":"Niedbala","year":"1985","journal-title":"Exp. Cell Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105312_bib130","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105312_bib131","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.bbalip.2013.02.010","article-title":"Adipose tissue and adipocytes support tumorigenesis and metastasis","volume":"1831","author":"Nieman","year":"2013","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Biology Lipids"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105312_bib132","article-title":"Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial","volume":"40","author":"Nishio","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib133","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.humpath.2021.04.003","article-title":"Expression of B7\u2013H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas","volume":"113","author":"Niu","year":"2021","journal-title":"Hum. Pathol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105312_bib134","article-title":"\"GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer","volume":"41","author":"O'Malley","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib135","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.1016\/j.annonc.2024.08.776","article-title":"714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the phase II TROPION-PanTumor03 study","volume":"35","author":"Oaknin","year":"2024","journal-title":"Ann. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105312_bib136","volume":"41","author":"Oaknin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib137","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ygyno.2016.09.018","article-title":"Phase II study of Vigil\u00ae DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer","volume":"143","author":"Oh","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105312_bib138","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117065119","article-title":"Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155\/TIGIT axis","volume":"119","author":"Ozmadenci","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105312_bib139","article-title":"Oregovomab in combination with non-platinum chemotherapy for the treatment of PARP inhibitor\u2013 and platinum-resistant ovarian cancer: A two-cohort, single-arm phase 2 study (OPERA\/KGOG3065\/APGOT-OV6)","volume":"43","author":"Park","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105312_bib140","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007444","article-title":"Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046\/TRU-D","volume":"11","author":"Park","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105312_bib141","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow Michael","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105312_bib142","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib143","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"\"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105312_bib144","doi-asserted-by":"crossref","first-page":"28","DOI":"10.25259\/Cytojournal_241_2024","article-title":"A new perspective: Acyl-CoA synthetase long-chain family member 4 inhibits ubiquitin-specific protease 7-induced epithelial ovarian cancer progression by inducing ferroptosis and M1 macrophage polarization","volume":"22","author":"Qi","year":"2025","journal-title":"Cytojournal"},{"key":"10.1016\/j.critrevonc.2026.105312_bib145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ygyno.2023.10.005","article-title":"Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE\/GOG-3032)","volume":"178","author":"Randall","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib146","doi-asserted-by":"crossref","first-page":"S1585","DOI":"10.1016\/j.annonc.2025.09.054","article-title":"LBA42 Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01.","volume":"36","author":"Ray-Coquard","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib147","doi-asserted-by":"crossref","first-page":"S671","DOI":"10.1016\/j.annonc.2025.08.1707","article-title":"1067P Results from the first-in-human phase I study of LY4170156, an antibody drug conjugate (ADC) targeting folate receptor alpha in recurrent platinum resistant high-grade serous ovarian cancer (HGSOC)","volume":"36","author":"Ray-Coquard","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109097","article-title":"Boosting bioavailability of PROTACs for ovarian cancer: From chemistry to clinical translation","volume":"166","author":"Rejili","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105312_bib149","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/0008-5472.CAN-05-1292","article-title":"Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells","volume":"66","author":"Ren","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105312_bib150","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.ygyno.2024.07.085","article-title":"UPLIFT (ENGOT-OV67\/GOG-3048): results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer","volume":"190","author":"Richardson","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib151","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003190","article-title":"Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial","volume":"10","author":"Rob","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105312_bib152","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1038\/s41591-022-02096-4","article-title":"Using genetics to predict toxicity of cancer immunotherapy","volume":"28","author":"Robert","year":"2022","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105312_bib153","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S1470-2045(20)30533-7","article-title":"Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III\/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"21","author":"Rocconi","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib154","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ygyno.2021.03.009","article-title":"Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer","volume":"161","author":"Rocconi","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105312_bib155","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1006\/gyno.2000.6042","article-title":"Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta","volume":"80","author":"Rodriguez","year":"2001","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105312_bib156","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2012.46.4057","article-title":"Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study","volume":"31","author":"Sabbatini","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib157","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2353\/ajpath.2007.060903","article-title":"Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer","volume":"170","author":"Said","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105312_bib158","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1593\/neo.08672","article-title":"SPARC Ameliorates Ovarian Cancer-Associated Inflammation","volume":"10","author":"Said","year":"2008","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105312_bib159","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/ijgc-2022-003927","article-title":"Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study","volume":"33","author":"Santin","year":"2023","journal-title":"Int J. Gynecol. Cancer"},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105312_bib160","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib161","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijgc.2025.102614","article-title":"A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL TO COMPARE RINATABART SESUTECAN VERSUS INVESTIGATOR's CHOICE OF CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: RAINFOL\u2122-02 (ENGOT-OV86\/GOG-3107).","volume":"35","author":"Secord","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105312_bib162","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/IGC.0b013e318263ef34","article-title":"Fibrillar Type I Collagen Matrices Enhance Metastasis\/Invasion of Ovarian Epithelial Cancer Via \u03b21 Integrin and PTEN Signals","volume":"22","author":"Shen","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105312_bib163","doi-asserted-by":"crossref","first-page":"S551","DOI":"10.1016\/j.annonc.2024.08.782","article-title":"720MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): results from a phase I study","volume":"35","author":"Shu","year":"2024","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105312_bib164","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1158\/0008-5472.CAN-08-2678","article-title":"Vascular cell adhesion molecule-1 Is a regulator of ovarian cancer peritoneal metastasis","volume":"69","author":"Slack-Davis","year":"2009","journal-title":"Cancer Res."},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105312_bib165","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1200\/EDBK_160766","article-title":"Biomarkers for immunotherapy: current developments and challenges","author":"Spencer","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105312_bib166","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1158\/1541-7786.MCR-21-0411","article-title":"The Spatial Context of Tumor-Infiltrating Immune Cells Associates with Improved Ovarian Cancer Survival","volume":"19","author":"Steinhart","year":"2021","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105312_bib167","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1387281","article-title":"Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group","author":"Stiegeler","year":"2024","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib168","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib169","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer Journal Clinicians"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105312_bib170","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1158\/1078-0432.CCR-20-0103","article-title":"Development and validation of the gene expression predictor of high-grade serous ovarian carcinoma molecular SubTYPE (PrOTYPE)","volume":"26","author":"Talhouk","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105312_bib171","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/cas.12445","article-title":"Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment","volume":"105","author":"Tanizaki","year":"2014","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105312_bib172","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2017.08.001","volume":"147","author":"Thaker","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105312_bib173","volume":"43","author":"Thaker","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"7353","key":"10.1016\/j.critrevonc.2026.105312_bib174","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105312_bib175","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105312_bib176","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1470-2045(25)00021-X","article-title":"Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor \u03b1-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial","volume":"26","author":"Van Gorp","year":"2025","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib177","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.trecan.2021.12.003","article-title":"When breaks get hot: inflammatory signaling in BRCA1\/2-mutant cancers","volume":"8","author":"van Vugt","year":"2022","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105312_bib178","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1\u2013positive advanced ovarian cancer: analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"7941","key":"10.1016\/j.critrevonc.2026.105312_bib179","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"V\u00e1zquez-Garc\u00eda","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105312_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101704","article-title":"Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43\/GOG-3036\/KEYLYNK-001 Study","volume":"35","author":"Vergote","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105312_bib181","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1548897","article-title":"Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota","volume":"16","author":"Vogrig","year":"2025","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib182","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/0008-5472.CAN-20-1674","article-title":"Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer","volume":"81","author":"Wan","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105312_bib183","first-page":"S548","article-title":"715MO Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol."},{"issue":"191","key":"10.1016\/j.critrevonc.2026.105312_bib184","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.24976\/Discov.Med.202436191.224","article-title":"Role of KIF20A Depletion in Inhibiting Ovarian Cancer Progression: Insights From PTEN and M2 Macrophage Polarization","volume":"36","author":"Wang","year":"2024","journal-title":"Discov. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib185","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/imm.13793","article-title":"Immunotherapy and the ovarian cancer microenvironment: exploring potential strategies for enhanced treatment efficacy","volume":"173","author":"Wang","year":"2024","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib186","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105312_bib187","doi-asserted-by":"crossref","first-page":"A255","DOI":"10.1136\/ijgc-2023-IGCS.481","article-title":"TP021\/#1540\u2005Reframe-O1\/ENGOT-OV79\/GOG-3086: a phase 2\/3 open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator\u2019s choice chemotherapy in relapsed platinum-resistant EOC expressing folate receptor-alpha","volume":"33","author":"Wendel Naumann","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105312_bib188","doi-asserted-by":"crossref","DOI":"10.1593\/tlo.13529","article-title":"Epithelial ovarian cancer-induced angiogenic phenotype of human omental microvascular endothelial cells may occur independently of VEGF signaling","volume":"6","author":"Winiarski","year":"2013","journal-title":"Transl. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105312_bib189","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1158\/0008-5472.CAN-12-4366","article-title":"IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment","volume":"73","author":"Wong","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105312_bib190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00024","article-title":"The unique molecular and cellular microenvironment of ovarian cancer","volume":"7","author":"Worzfeld","year":"2017","journal-title":"Front. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105312_bib191","article-title":"JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): updated findings from two clinical trials","volume":"43","author":"Wu","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib192","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003831","article-title":"Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study","volume":"10","author":"Xia","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"180","key":"10.1016\/j.critrevonc.2026.105312_bib193","doi-asserted-by":"crossref","first-page":"113","DOI":"10.24976\/Discov.Med.202436180.10","article-title":"CircRNA Hsa_circ_0120175 promotes ovarian cancer tumorigenesis and predicts a poor prognosis","volume":"36","author":"Xing","year":"2024","journal-title":"Discov. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib194","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001136","article-title":"CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer","volume":"9","author":"Yang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105312_bib195","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/EDBK_180328","article-title":"Adoptive T-Cell Therapy for Solid Tumors","volume":"37","author":"Yeku","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105312_bib196","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1158\/0008-5472.CAN-13-0023","article-title":"TGF-\u03b2 modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment","volume":"73","author":"Yeung","year":"2013","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105312_bib197","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: an NRG Oncology Study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105312_bib198","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1002\/cam4.3942","article-title":"Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105312_bib199","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105312_bib200","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1038\/s41467-019-13116-2","article-title":"Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105312_bib201","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/cgt.2015.7","article-title":"Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer","volume":"22","author":"Zhang","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.critrevonc.2026.105312_bib202","article-title":"The role of B7-H4 in ovarian cancer immunotherapy: current status, challenges, and perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105312_bib203","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41416-024-02803-7","article-title":"Integrated immuno-transcriptomic analysis of ovarian cancer identifies a four-chemokine-dominated subtype with antitumor immune-active phenotype and favorable prognosis","volume":"131","author":"Zhuo","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105312_bib204","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody\u2013drug conjugates in cancer treatment","author":"Zippelius","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105312_fur1","doi-asserted-by":"crossref","first-page":"S550","DOI":"10.1016\/j.annonc.2024.08.781","article-title":"719MO A phase I\/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer","volume":"35","author":"Lee","year":"2024","journal-title":"Ann. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600199X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600199X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:05:12Z","timestamp":1780038312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600199X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":205,"alternative-id":["S104084282600199X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105312","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy advancements in high-grade serous ovarian cancer: From promise to practice","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105312"}}